PSA screening tied to lower risk of prostate cancer mortality
Prostate-specific antigen (PSA) screening is associated with decreased risk of prostate cancer-specific mortality (PCSM) among both Black and White men, according to a study published online Aug. 4 in JAMA Oncology.